An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2019
At a glance
- Drugs Avapritinib (Primary)
- Indications Systemic mastocytosis
- Focus Registrational; Therapeutic Use
- Acronyms PATHFINDER
- Sponsors Blueprint Medicines
- 04 Jan 2019 According to a Blueprint Medicines media release, enrollement is expected to complete in the second half of 2019.
- 04 Jan 2019 According to a Blueprint Medicines media release, patient dosing has been initiated .
- 09 Nov 2018 Planned End Date changed from 1 Oct 2023 to 1 Nov 2023.